Further Evidence in Favor of Non-Invasive Vasospasm Diagnosis

Non-invasive coronary vasospasm diagnosis by means of echocardiography with the administration of ergonovine can be performed safely; even without prior angiography to rule out fixed lesions.

These data are encouraging and move patients with vessel spasm but without significant lesions away from multiple angiographies and from the uncertainty of a diagnosis “by exclusion.”

This work recently published in JACC Cardiovasc Imaging sought large-scale evidence to support the clinical utility of ergonovine echocardiography for the diagnosis of coronary spasms.

The test was performed in 14,012 patients (mean age 52 years; 44.3% were women) after ruling out significant coronary arterial stenosis by functional (stress electrocardiography or single photon emission computed tomography [SPECT], n = 9,824) or anatomic testing (tomography or conventional angiography, n = 4,188).

Only 0.4% of patients had to stop the study early, and a positive result was obtained in 2144 patients (15.3%). Said positive result had variable frequencies according to the presumptive diagnosis for each patient at baseline (acute coronary syndrome [38.2%], variant angina [31.8%], effort angina [14.9%], aborted sudden cardiac death [17.6%], and syncope [9.9%]).


Read also: Diabetes Could Decide between Ticagrelor and Prasugrel.


There were no mortality or infarction events during the study with ergonovine.

During a median follow-up of 11.4 years (range: 7.2 to 15.8), all-cause death and cardiovascular death occurred in 494 and 143 patients, respectively.

Compared with patients with positive ergonovine test results, the functional test group and the anatomic test group did not show a significant difference in events.


Read also: How To De-Escalate Prasugrel After Acute Coronary Syndrome?


After multiple adjustments, having a positive ergonovine echocardiogram was an independent factor linked to all-cause mortality (hazard ratio [HR]: 1.879, p < 0.001) and cardiovascular death (HR: 2.903, p < 0.001).

Conclusion

Ergonovine echocardiography may be a safe diagnostic tool for coronary vasospasm, even without anatomic documentation. These results have major long-term prognosis implications, and might even replace invasive provocation testing.

Original Title: Diagnostic and Prognostic Value of Ergonovine Echocardiography for Noninvasive Diagnosis of Coronary Vasospasm.

Reference: Sang Yong Om et al. JACC Cardiovasc Imaging. 2020 Sep;13(9):1875-1887. doi: 10.1016/j.jcmg.2020.03.008.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

High Ischaemic Risk Criteria in Chronic Coronary Syndrome: Prevalence and Prognosis

Despite advances in the management of chronic coronary syndrome (CCS), including the widespread use of drug-eluting stents (DES) and the optimization of medical therapy,...

ACC 2026 | DKCRUSH VIII: IVUS or angiography to guide PCI in complex coronary bifurcations

Intracoronary imaging guidance has become an established recommended strategy in complex coronary lesions. In the specific setting of complex bifurcations, uncertainty remained regarding the...

ACC 2026 | OPTIMAL: IVUS Guidance in PCI of the Unprotected Left Main Coronary Artery

Percutaneous coronary intervention (PCI) is considered an equivalent alternative to coronary artery bypass surgery in patients with left main coronary artery (LMCA) stenosis and...

ACC 2026 | IVUS-CHIP Trial: Intravascular ultrasound–guided versus angiography-guided complex PCI

Optimization of percutaneous coronary intervention (PCI) in complex lesions remains a relevant clinical challenge. In this context, the IVUS-CHIP trial was designed to evaluate...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

High Ischaemic Risk Criteria in Chronic Coronary Syndrome: Prevalence and Prognosis

Despite advances in the management of chronic coronary syndrome (CCS), including the widespread use of drug-eluting stents (DES) and the optimization of medical therapy,...

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...